<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Intraventricular hemorrhage</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Intraventricular hemorrhage</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Intraventricular hemorrhage</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Brett L Cucchiara, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Scott E Kasner, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alejandro A Rabinstein, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard P Goddeau, Jr, DO, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 26, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Intraventricular hemorrhage (IVH) confined to the ventricular system within the brain is uncommon, accounting for only about 3 percent of all spontaneous intracranial hemorrhage [<a href="#rid1">1</a>]. IVH more commonly occurs in the setting of intracerebral hemorrhage or subarachnoid hemorrhage.</p><p>The assessment of the patient with IVH focuses on identifying the underlying cause of the hemorrhage, which may have significant treatment implications. Common to patients with IVH, regardless of etiology, is a risk for sudden and potentially fatal obstructive hydrocephalus, requiring acute clinical decision-making regarding the use of external ventricular drainage and other interventions.</p><p>This topic discusses the causes, clinical presentation, diagnosis, and treatment of IVH. Intracerebral, subarachnoid, subdural, and epidural hemorrhage are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1133.html" rel="external">"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1084.html" rel="external">"Spontaneous intracerebral hemorrhage: Acute treatment and prognosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1130.html" rel="external">"Aneurysmal subarachnoid hemorrhage: Clinical manifestations and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1127.html" rel="external">"Aneurysmal subarachnoid hemorrhage: Treatment and prognosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1105.html" rel="external">"Subdural hematoma in adults: Etiology, clinical features, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1110.html" rel="external">"Subdural hematoma in adults: Management and prognosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1107.html" rel="external">"Intracranial epidural hematoma in adults"</a>.)</p><p></p><p>IVH in the newborn is also discussed separately. (See  <a class="medical medical_review" href="/d/html/5051.html" rel="external">"Germinal matrix and intraventricular hemorrhage (GMH-IVH) in the newborn: Risk factors, clinical features, screening, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/5000.html" rel="external">"Germinal matrix and intraventricular hemorrhage (GMH-IVH) in the newborn: Management and outcome"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY AND DEFINITIONS</span><span class="headingEndMark"> — </span>Primary IVH refers to bleeding confined to the ventricular system within the brain. Primary IVH is uncommon, accounting for only about 3 percent of all spontaneous intracerebral hemorrhage [<a href="#rid1">1</a>]. The following demographic characteristics were reported in a 2008 review of published cases series of primary IVH [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The median age is 55 years (range 9 to 91 years).</p><p class="bulletIndent1"><span class="glyph">●</span>Males and females are equally represented.</p><p class="bulletIndent1"><span class="glyph">●</span>Half of patients have a history of hypertension.</p><p></p><p>Secondary IVH refers to the more common occurrence of IVH in the setting of intracerebral hemorrhage or subarachnoid hemorrhage. The epidemiology of intracerebral hemorrhage and subarachnoid hemorrhage is discussed separately. (See  <a class="medical medical_review" href="/d/html/1133.html" rel="external">"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/1130.html" rel="external">"Aneurysmal subarachnoid hemorrhage: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>IVH most commonly occurs as a secondary phenomenon when parenchymal or intracerebral hemorrhage (ICH) ruptures into the ventricular space or when subarachnoid hemorrhage (SAH) extends into the ventricles. IVH is estimated to complicate 40 to 60 percent of ICH and 10 percent of SAH cases [<a href="#rid3">3-5</a>]. In one retrospective review, <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> therapy was associated with IVH risk, volume at presentation, and subsequent expansion in patients with deep or lobar ICH [<a href="#rid6">6</a>]. The underlying causes of ICH and SAH are discussed separately. (See  <a class="medical medical_review" href="/d/html/1133.html" rel="external">"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/1130.html" rel="external">"Aneurysmal subarachnoid hemorrhage: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/1111.html" rel="external">"Nonaneurysmal subarachnoid hemorrhage"</a>.)</p><p>IVH can also complicate closed head injury. Usually, this is in the setting of other traumatic brain injury, including contusion and traumatic SAH; isolated IVH is a relatively rare complication of head trauma [<a href="#rid7">7-9</a>].</p><p>Primary IVH is uncommon; in consequence, studies estimating the frequency of various etiologies have been limited. Retrospective case series derived from tertiary referral centers are subject to ascertainment bias. Further, definitions of primary IVH have varied among different authors and studies. While most limit their use of the term to hemorrhages entirely localized within the ventricle, others have included hemorrhages that originate within 15 mm of the ependymal surface [<a href="#rid10">10</a>]. The latter criteria invariably classify thalamic, caudate, and medial putaminal bleeds (usually secondary to chronic hypertension) associated with IVH as primary IVH.</p><p>Among series that more strictly limit the definition of IVH, vascular malformations are the most frequently identified cause of primary IVH. In small case series, vascular malformations have been identified in 14 to 58 percent of patients with primary IVH [<a href="#rid2">2,10-15</a>]. Reported causes of primary IVH include:</p><p class="bulletIndent1"><span class="glyph">●</span>Vascular malformations (usually arteriovenous malformations or arteriovenous fistulas) [<a href="#rid1">1,2,10-19</a>]. (See  <a class="medical medical_review" href="/d/html/1087.html" rel="external">"Brain arteriovenous malformations"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intraventricular tumors (papilloma, neurocytoma, meningioma, metastases, astrocytoma, ependymoma) [<a href="#rid11">11,20-26</a>]. (See  <a class="medical medical_review" href="/d/html/5180.html" rel="external">"Overview of the clinical features and diagnosis of brain tumors in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intraventricular aneurysms developing within the distal lenticulostriate or choroidal arteries (occasionally reported in association with Moyamoya disease) [<a href="#rid10">10,16,22,27</a>]. Occasionally aneurysms of the anterior communicating artery, posterior inferior cerebellar artery, or basilar tip rupture into the ventricles without other overt subarachnoid blood [<a href="#rid2">2,10,14</a>]. (See  <a class="medical medical_review" href="/d/html/1130.html" rel="external">"Aneurysmal subarachnoid hemorrhage: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Moyamoya disease [<a href="#rid1">1,2,16,22,28-31</a>]. (See  <a class="medical medical_review" href="/d/html/1131.html" rel="external">"Moyamoya disease and moyamoya syndrome: Etiology, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Coagulopathies, acquired or inherited [<a href="#rid2">2,10,12,29,32-34</a>]. (See  <a class="medical medical_review" href="/d/html/1326.html" rel="external">"Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pituitary apoplexy [<a href="#rid35">35</a>]. (See  <a class="medical medical_review" href="/d/html/6632.html" rel="external">"Causes, presentation, and evaluation of sellar masses", section on 'Causes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vasculitis [<a href="#rid36">36</a>]. (See  <a class="medical medical_review" href="/d/html/8230.html" rel="external">"Primary angiitis of the central nervous system in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fibromuscular dysplasia [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/d/html/3874.html" rel="external">"Clinical manifestations and diagnosis of fibromuscular dysplasia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sympathomimetic agents [<a href="#rid37">37,38</a>]. (See  <a class="medical medical_review" href="/d/html/4953.html" rel="external">"Clinical manifestations, diagnosis, and management of the cardiovascular complications of cocaine abuse"</a> and  <a class="medical medical_review" href="/d/html/82952.html" rel="external">"Acute amphetamine and synthetic cathinone ("bath salt") intoxication", section on 'Central and peripheral nervous system'</a>.)</p><p></p><p>In approximately 20 to 50 percent of cases (depending in part on the intensity of the investigation), no cause is identified [<a href="#rid11">11,12,16,33</a>]. About half of these patients have chronic hypertension; this is believed, but not known, to cause primary IVH in the same way it is understood to cause ICH. It is speculated that some patients with IVH may have had a small hypertensive intraparenchymal hemorrhage, too small to see on computed tomography (CT) or magnetic resonance imaging (MRI), which arises in proximity to the ventricular system and produces IVH as its primary manifestation. (See  <a class="medical medical_review" href="/d/html/1133.html" rel="external">"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis", section on 'Pathogenesis and etiologies'</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H5"><span class="h2">Clinical presentation</span><span class="headingEndMark"> — </span>Patients with secondary IVH present with clinical features typical of intracerebral hemorrhage or subarachnoid hemorrhage. (See  <a class="medical medical_review" href="/d/html/1133.html" rel="external">"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/1130.html" rel="external">"Aneurysmal subarachnoid hemorrhage: Clinical manifestations and diagnosis"</a>.)</p><p>Patients with primary IVH typically present with abrupt headache, often associated with nausea, vomiting, and impaired consciousness (confusion, disorientation) [<a href="#rid2">2,11,33,39</a>]. A minority of patients have frank loss of consciousness at the onset [<a href="#rid12">12</a>]. Symptoms are usually sudden in onset; however, nearly a quarter of patients are reported to have progressive or fluctuating symptoms [<a href="#rid11">11,12</a>]. The degree of neurologic impairment, often measured as the Glasgow Coma Scale  (<a class="graphic graphic_table graphicRef81854" href="/d/graphic/81854.html" rel="external">table 1</a>) is an important prognostic indicator. (See <a class="local">'Prognosis'</a> below.)</p><p>Focal neurologic findings are relatively uncommon with primary IVH and most typically involve cranial nerve abnormalities [<a href="#rid10">10</a>]. Such cranial nerve palsies are generally of the "false localizing" type due to stretching across the basilar skull surface and include dysfunction of the sixth and third nerves. Seizures are not common but can occur [<a href="#rid1">1,10,11,17</a>]. Most patients are hypertensive on presentation, and some will have an elevated body temperature or suffer cardiac arrhythmias [<a href="#rid12">12</a>]. Nuchal rigidity is inconsistently present.</p><p>The clinical symptoms and signs of IVH reflect a sudden increase in intracranial pressure that results from sudden introduction of blood volume into the intracranial space [<a href="#rid40">40</a>]. In addition to pressure effects, it is speculated that blood products in the cerebrospinal fluid space may affect brain function.</p><p class="headingAnchor" id="H6"><span class="h2">Complications</span><span class="headingEndMark"> — </span>Patients with primary or secondary IVH are at risk for sudden neurologic deterioration, which may result from obstructive hydrocephalus, recurrent hemorrhage, or other complications [<a href="#rid12">12</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hydrocephalus</strong> – Acute obstructive hydrocephalus can result when cerebrospinal fluid circulation is obstructed by blood clots. Patients with blood in the third or fourth ventricle are at most risk of this complication [<a href="#rid12">12</a>]. One-half to two-thirds of patients with IVH have some degree of hydrocephalus on the initial computed tomography (CT) scan of the head [<a href="#rid2">2,11,12,15,41</a>]. This can be rapidly fatal and usually requires urgent intervention with insertion of an external ventricular drain [<a href="#rid8">8,40</a>]. (See <a class="local">'External ventricular drain'</a> below.)</p><p></p><p class="bulletIndent1">Patients may also develop communicating hydrocephalus as a delayed complication of IVH; this usually presents more gradually. (See <a class="local">'Prognosis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemorrhage extension</strong> – Recurrent hemorrhage or hemorrhage extension occurs in up to 20 to 25 percent of patients with IVH [<a href="#rid12">12,40,42,43</a>]. The highest risk of this is in those with an underlying etiology of vascular malformation or aneurysm or in the setting of a coagulopathy. The presence of a coexisting intraparenchymal hemorrhage is also associated with an elevated risk of IVH expansion, especially those that have expanded on follow-up imaging or are located in the thalamus [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cerebral vasospasm</strong> – Cerebral ischemia due to arterial vasospasm is unusual in cases of primary IVH, but this complication has been described in isolated cases [<a href="#rid19">19,44-46</a>]. In contrast, vasospasm is a common complication of aneurysmal subarachnoid hemorrhage. (See  <a class="medical medical_review" href="/d/html/1130.html" rel="external">"Aneurysmal subarachnoid hemorrhage: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other medical complications </strong>– Neurologic deterioration due to medical complications is common in the setting of IVH. These include pulmonary embolism, pneumonia and other infections, and electrolyte imbalance. Other medical complications of IVH include cardiovascular instability, deep venous thrombosis, and gastrointestinal bleeding.</p><p></p><p class="headingAnchor" id="H7"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The presentation of primary IVH overlaps with those of aneurysmal subarachnoid hemorrhage and other forms of stroke. Urgent diagnostic evaluation, including head CT, is required to identify these alternative conditions to reduce risk of morbidity and initiate time-sensitive therapeutic interventions. (See  <a class="medical medical_review" href="/d/html/1130.html" rel="external">"Aneurysmal subarachnoid hemorrhage: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/115775.html" rel="external">"Approach to reperfusion therapy for acute ischemic stroke"</a> and  <a class="medical medical_review" href="/d/html/1084.html" rel="external">"Spontaneous intracerebral hemorrhage: Acute treatment and prognosis"</a> and  <a class="medical medical_review" href="/d/html/1109.html" rel="external">"Cerebral venous thrombosis: Treatment and prognosis"</a>.)</p><p>Other conditions that may present with a headache with sudden onset also include reversible cerebral vasoconstriction syndrome, cervical artery dissection, and posterior reversible leukoencephalopathy syndrome, among others  (<a class="graphic graphic_table graphicRef81710" href="/d/graphic/81710.html" rel="external">table 2</a>). A noncontrast head CT can distinguish IVH from these other entities. (See  <a class="medical medical_review" href="/d/html/3346.html" rel="external">"Overview of thunderclap headache", section on 'Diagnostic evaluation'</a>.)</p><p class="headingAnchor" id="H8"><span class="h1">DIAGNOSTIC EVALUATION</span></p><p class="headingAnchor" id="H141008367"><span class="h2">Imaging diagnosis</span><span class="headingEndMark"> — </span>Noncontrast head CT is the test of choice to diagnose IVH. CT rapidly and reliably identifies blood within the ventricular system, helps to identify parenchymal intracerebral hemorrhage (ICH) or subarachnoid hemorrhage (SAH) associated with the IVH, and also identifies concurrent hydrocephalus.</p><p>IVH may be identified infrequently by brain MRI or other neuroimaging studies, typically when these studies are performed to evaluate other conditions.</p><p class="headingAnchor" id="H2800716663"><span class="h2">Evaluation for underlying causes and monitoring</span><span class="headingEndMark"> — </span>Neuroimaging studies are typically required to define the etiology of a primary IVH. In the absence of an obvious precipitant such as trauma or coagulopathy, we recommend patients with primary IVH undergo neuroimaging to assess for underlying causes.</p><p class="headingAnchor" id="H9"><span class="h3">Computed tomography</span><span class="headingEndMark"> — </span>Close examination of the initial head CT should be performed to identify secondary IVH due to ICH or aneurysmal SAH. Hemorrhagic findings in the brain regions surrounding the ventricles (caudate and thalamus, in particular) may identify ICH  (<a class="graphic graphic_diagnosticimage graphicRef132277" href="/d/graphic/132277.html" rel="external">image 1</a>). Similarly, the presence of subarachnoid blood in the basal cisterns or cortical sulci should raise concern for aneurysmal SAH with secondary IVH. If ICH or SAH is present, diagnostic evaluation should be pursued. (See  <a class="medical medical_review" href="/d/html/1133.html" rel="external">"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis", section on 'Evaluation and diagnosis'</a> and  <a class="medical medical_review" href="/d/html/1130.html" rel="external">"Aneurysmal subarachnoid hemorrhage: Clinical manifestations and diagnosis", section on 'Identifying the source of bleeding'</a>.)</p><p>The extent of IVH can be graded by head CT. The Graeb score and other scoring systems have been proposed [<a href="#rid47">47-49</a>], but none are widely implemented in clinical practice.</p><p>The CT scan should be repeated emergently for any neurologic deterioration to identify recurrent hemorrhage or obstructive hydrocephalus. Acute imaging findings associated with an elevated risk of IVH growth include irregular hemorrhage shape, intralesional hypodensity, and coexisting intraparenchymal hemorrhage [<a href="#rid42">42,43</a>]. CT scans are also used to monitor hydrocephalus, particularly during attempts to clamp or remove a drain. Transcranial ultrasonography has been suggested as a possible alternative to serial CT to monitor ventricular size, but the reliability and reproducibility of this technique has yet to be independently validated [<a href="#rid50">50</a>].</p><p class="headingAnchor" id="H10"><span class="h3">Other neuroimaging studies</span><span class="headingEndMark"> — </span>For most patients with IVH, we typically start with MRI and magnetic resonance angiography (MRA) or CT angiography to investigate for underlying causes  (<a class="graphic graphic_diagnosticimage graphicRef132281" href="/d/graphic/132281.html" rel="external">image 2</a>). If the MRI/MRA or CT angiography is unrevealing, we recommend digital subtraction angiography, in agreement with guidelines from the American Heart Association/American Stroke Association [<a href="#rid51">51</a>].</p><p>In a prospective observational study of patients with IVH who underwent catheter angiography, vascular lesions were found in 11 of 17 (65 percent), including 10 patients with arteriovenous malformations, and one with aneurysm [<a href="#rid14">14</a>]. A retrospective review of published case series similarly estimated the yield of angiography at 56 percent, additionally identifying cases of Moyamoya and dural arteriovenous fistula [<a href="#rid2">2</a>]. If the cause of the IVH remains undetermined, it is reasonable in some cases to consider repeat contrast MRI and possibly catheter angiography one to two months following the initial studies after reabsorption of blood products has occurred.</p><p class="headingAnchor" id="H11"><span class="h2">Other tests</span><span class="headingEndMark"> — </span>Other tests that are important to include are blood clotting studies (prothrombin time, partial thromboplastin time, and platelet count). A toxicology screen should also be considered.</p><p>Because electrolyte imbalances can complicate IVH, these should be measured at baseline and followed regularly.</p><p class="headingAnchor" id="H12"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H13"><span class="h2">General measures</span><span class="headingEndMark"> — </span>The treatment of IVH focuses on cessation of bleeding, relieving hydrocephalus, and controlling intracranial pressure (ICP).</p><p>Specific therapy aimed at treating the underlying cause should be undertaken (aneurysm or arteriovenous malformation obliteration). (See  <a class="medical medical_review" href="/d/html/1127.html" rel="external">"Aneurysmal subarachnoid hemorrhage: Treatment and prognosis"</a> and  <a class="medical medical_review" href="/d/html/1129.html" rel="external">"Vascular malformations of the central nervous system"</a>.)</p><p>Patients who have a moderate to severe IVH (impaired alertness and/or extensive intraventricular blood on imaging) should be followed in an intensive care setting. Medical complications are common (eg, pneumonia, deep venous thrombosis, gastrointestinal bleeding, cardiovascular instability, supraventricular tachycardia, hypo- and hypernatremia) and require appropriate monitoring and treatment [<a href="#rid1">1,11</a>]. The head of the bed should be placed at 30 degrees or greater to decrease ICP and reduce the risk of aspiration. Euvolemia should be maintained using isotonic crystalloid solutions, and any elevations in body temperature should be treated aggressively.</p><p>For prevention of deep venous thrombosis, mechanical thromboprophylaxis using intermittent pneumatic compression stockings is recommended until a bleeding source has been identified and secured. At that time, antithrombotic therapy can be used. (See  <a class="medical medical_review" href="/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"</a>.)</p><p>Because seizures are an infrequent complication of IVH, prophylactic antiseizure medications are not generally used but should be initiated immediately should seizures occur.</p><p class="headingAnchor" id="H2806883312"><span class="h2">Management of antithrombotic medications</span></p><p class="headingAnchor" id="H2135354307"><span class="h3">Reversing anticoagulation</span><span class="headingEndMark"> — </span>For most patients with IVH, we discontinue anticoagulant medications and give agents to reverse their effects. However, for some patients with small acute IVH and no signs of hydrocephalus who are receiving anticoagulation for a compelling indication such as a mechanical heart valve, the risk-benefit calculation may favor continued anticoagulation with close observation of neurologic status. In such circumstances, we generally use intravenous heparin during the acute period given the ability to rapidly reverse its anticoagulant effect. (See  <a class="medical medical_review" href="/d/html/104830.html" rel="external">"Anticoagulation for prosthetic heart valves: Management of bleeding and invasive procedures", section on 'Management of bleeding'</a>.)</p><p>If reversal of anticoagulation is indicated, the appropriate intervention depends upon the anticoagulant the patient is taking, the time since last dose, and the urgency with which reversal is needed. Some patients prescribed anticoagulant medications may not require reversal agents if laboratory testing or the time interval since last dose indicates they are effectively not anticoagulated.</p><p>The strategies used to reverse anticoagulation in patients with IVH are the same as those used for patients with intracerebral hemorrhage. These strategies are discussed separately. (See  <a class="medical medical_review" href="/d/html/1325.html" rel="external">"Reversal of anticoagulation in intracranial hemorrhage", section on 'Reversal strategy for specific anticoagulants'</a>.)</p><p class="headingAnchor" id="H3895522767"><span class="h3">Patients on antiplatelets</span><span class="headingEndMark"> — </span>Antiplatelet medications are typically stopped at the time of diagnosis for most patients with acute IVH. However, we balance the thrombotic risks of discontinuation with the hemorrhagic risks of continuing antiplatelets at an individual level. We may continue antiplatelet medications during acute monitoring for selected patients at high risk of thrombosis such as those with established atherosclerotic disease or who have undergone intravascular stent placement and who have small IVH. (See  <a class="medical medical_review" href="/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk"</a> and  <a class="medical medical_review" href="/d/html/1576.html" rel="external">"Antithrombotic therapy for elective percutaneous coronary intervention: General use"</a> and  <a class="medical medical_review" href="/d/html/1104.html" rel="external">"Overview of carotid artery stenting"</a> and  <a class="medical medical_review" href="/d/html/15217.html" rel="external">"Endovascular techniques for lower extremity revascularization", section on 'Antiplatelet therapy'</a>.) </p><p>We reserve platelet transfusions for those with specific indications, including those with a thrombocytopenia (&lt;100,000/microL) or a known platelet defect. (See  <a class="medical medical_review" href="/d/html/7918.html" rel="external">"Platelet transfusion: Indications, ordering, and associated risks", section on 'Platelet function disorders'</a>.)</p><p class="headingAnchor" id="H14"><span class="h2">Blood pressure management</span><span class="headingEndMark"> — </span>The optimal blood pressure management in patients with IVH remains undefined. Aggressive blood pressure lowering may minimize the risk of further hemorrhage but must be weighed against the risk of decreased cerebral perfusion in patients with increased ICP.</p><p>It seems reasonable to gradually lower elevated blood pressure in patients with normal ICP. Intravenous antihypertensives such as <a class="drug drug_general" data-topicid="9540" href="/d/drug information/9540.html" rel="external">labetalol</a> or <a class="drug drug_general" data-topicid="9697" href="/d/drug information/9697.html" rel="external">nicardipine</a> are typically used, although other agents are acceptable [<a href="#rid52">52</a>]. In the absence of better data specific to IVH, the guidelines outlined for blood pressure management in the setting of ICH seem reasonable [<a href="#rid51">51</a>]. (See  <a class="medical medical_review" href="/d/html/1084.html" rel="external">"Spontaneous intracerebral hemorrhage: Acute treatment and prognosis", section on 'Blood pressure management'</a>.)</p><p class="headingAnchor" id="H15"><span class="h2">External ventricular drain</span><span class="headingEndMark"> — </span>An external ventricular drain (EVD) is a small catheter inserted through the skull usually into the lateral ventricle, which is typically connected to a closed collecting device to allow for drainage of cerebrospinal fluid  (<a class="graphic graphic_figure graphicRef56391" href="/d/graphic/56391.html" rel="external">figure 1</a>). The EVD can also be connected to a transducer that records ICP.</p><p>We recommend an EVD for patients with IVH with hydrocephalus and neurologic decline [<a href="#rid51">51</a>]. Rarely, bilateral EVDs may be needed if hemorrhage obstructs the foramen of Monro [<a href="#rid53">53</a>].</p><p>The major complications associated with EVD are catheter occlusion due to clotted blood at the intraventricular orifice and infection. The former may be relieved by irrigation or catheter replacement. Symptoms suggestive of infection should prompt cerebrospinal fluid analysis for cell count and culture along with antibiotic therapy as appropriate. Staphylococci are the most common pathogens. Higher rates of bacterial ventriculitis/meningitis occur with longer duration of EVD placement [<a href="#rid54">54</a>]. Prophylactic catheter change does not reduce the risk of infection. The management and prevention of infections in patients with an EVD are discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/1286.html" rel="external">"Infections of cerebrospinal fluid shunts"</a>.)</p><p class="headingAnchor" id="H3444254798"><span class="h2">Additional management options</span><span class="headingEndMark"> — </span>In addition to EVD placement, adjunctive approaches have also been used for selected patients with IVH for the prevention and treatment of hydrocephalus.</p><p class="headingAnchor" id="H16"><span class="h3">Intraventricular thrombolysis</span><span class="headingEndMark"> — </span>The utility of intraventricular thrombolysis (IVT) for patients with IVH and an EVD is uncertain. IVT use involves shared decision-making and includes discussing individual risks and benefits. Instillation of thrombolytic agents into the ventricles may improve mortality by hastening clot resolution, thereby avoiding the morbidity associated with EVD occlusion and shortening the duration of EVD use. It is also possible, although unproven, that more rapid resolution of IVH may decrease the long-term incidence of communicating hydrocephalus. However, IVT use may increase the risk of bleeding and severe disability.</p><p>Evidence supporting the use of IVT for EVD has been reported in case series, observational studies, and pooled analyses. These studies have suggested a benefit for IVT, showing increased clot resolution and, in some cases, decreased mortality [<a href="#rid3">3,39,55-66</a>]. The results of randomized clinical trials, on the other hand, have not shown clear benefit:</p><p class="bulletIndent1"><span class="glyph">●</span>The Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage (CLEAR III) trial included 500 patients with IVH and compared treatment with 1 mg <a class="drug drug_general" data-topicid="8478" href="/d/drug information/8478.html" rel="external">alteplase</a> (tPA) or placebo injected through an EVD every eight hours until clot reduction or a clinical endpoint occurred, or 12 doses were given [<a href="#rid67">67</a>]. At 180 days, the primary efficacy outcome of a modified Rankin scale (mRS) score of 3 or less was similar in each group (48 versus 45 percent comparing alteplase to placebo; risk ratio [RR] 1.06, 95% CI 0.88-1.28). Patients who received IVT had a lower mortality (18 versus 29 percent; RR 0.60, 95% CI 0.41-0.86), but a higher rate of severe disability indicated by an mRS score of 5 (17 versus 9 percent; RR 1.99, 95% CI 1.22-3.26). Bleeding complication rates were similar (2 percent) in both groups. One criticism of the CLEAR-III trial is that only a minority of patients experienced substantial IVT removal, suggesting the possibility of benefit with more effective methods for clot removal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Intraventricular Hemorrhage Thrombolysis Trial, a multicenter randomized controlled study, enrolled 48 patients and compared IVT (3 mg tPA) to control (normal <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>); each treatment was injected through an EVD every 12 hours until clot reduction or a clinical endpoint occurred (median duration of dosing was 7.5 days for IVT) [<a href="#rid68">68</a>]. The rate of clot resolution was faster for IVT than placebo (18 versus 8 percent per day). Rates of death and ventriculitis were lower than expected and did not differ significantly between treatment groups. Symptomatic bleeding complications were more frequent in the tPA group (23 versus 5 percent), but this did not reach statistical significance. The dose used in this study was higher than that used in the CLEAR III trial.</p><p></p><p>Bleeding complications are a concern with IVT; recurrent IVH and/or ICH expansion is reported in 8 to 20 percent of patients after IVT [<a href="#rid16">16,40,57,58,68,69</a>]. Typically, patients with known aneurysm or vascular malformation were excluded from early studies of IVT. However, IVT has been used without complication in a few reported cases after the vascular malformation or aneurysm was surgically treated [<a href="#rid16">16,70-72</a>], and even before surgery, in few patients with these lesions [<a href="#rid17">17,73</a>]. Systemic bleeding complications are unlikely to be significantly increased with IVT; in CLEAR IVH, systemic coagulation parameters were similar after administration of tPA and placebo [<a href="#rid74">74</a>].</p><p>It is also possible that the risk of bacterial meningitis/ventriculitis may be increased with IVT therapy, but this has not been demonstrated so far [<a href="#rid40">40,57,67,68</a>]. IVT has not been associated with systemic complications [<a href="#rid75">75</a>].</p><p>IVT is reserved for selected patients with acute IVH and an EVD at centers experienced with this approach.</p><p class="headingAnchor" id="H17"><span class="h3">Lumbar drainage</span><span class="headingEndMark"> — </span>The use of lumbar drainage combined with IVT was studied in an open-label trial that was stopped early after 30 patients were enrolled; patients with severe IVH with tamponade of the third and fourth ventricles requiring EVD were treated with IVT (control group) or IVT combined with lumbar drainage [<a href="#rid76">76</a>]. The primary endpoint (need for permanent shunt placement of prolonged requirement for cerebrospinal fluid drainage) occurred more frequently in the control versus combined treatment groups (7 out of 16 versus 0 out of 14). In a meta-analysis that included patients in this study as well as an additional 67 patients treated outside of the clinical trial, the combined intervention was associated with a significant reduction (OR 0.24; 95% CI 0.01-0.36) for shunt dependency. This analysis found no significant differences in functional outcomes or cerebrospinal fluid infection rates at 90 days; bleeding complications were less frequent in the combined treatment group (odds ratio 0.4, 95% CI 0.30-0.53).</p><p class="headingAnchor" id="H18"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The reported in-hospital mortality of IVH varies from 20 to 50 percent [<a href="#rid1">1,2,4,10-12,33,57</a>]. Secondary IVH carries a higher risk of death than primary IVH [<a href="#rid15">15,33,75</a>]. Advanced age, underlying coagulopathy, Glasgow Coma Scale score of 8 or less, and hydrocephalus at presentation are also associated with a higher risk of death [<a href="#rid2">2,12,33,41,75</a>]. While some studies have found that the extent of IVH correlates with prognosis [<a href="#rid2">2,12,41,48</a>], others have not [<a href="#rid10">10,11,15</a>]. The results of one study found that the volume of blood in the third ventricle was a strong and independent predictor of poor outcomes, while the volume of blood in the lateral ventricles, fourth ventricle, or entire ventricular system did not correlate significantly with prognosis [<a href="#rid77">77</a>]. The authors speculated that blood in the third ventricle may affect critical contiguous structures in the midbrain.</p><p>Other long-term complications of IVH include:</p><p class="bulletIndent1"><span class="glyph">●</span>Neurocognitive sequelae – Patients with significant IVH are often confused, agitated, and disoriented [<a href="#rid1">1</a>]. These symptoms are often slow to recover and a significant proportion (about half of survivors) are left with disabling cognitive deficits [<a href="#rid1">1,11,16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Noncommunicating hydrocephalus – IVH along with a secondary inflammatory/fibrotic response may lead to impaired absorption of cerebrospinal fluid at the arachnoid granulations. This may be manifest by a more subacute decline in cognition, gait, and urinary continence that can occur weeks or later after the initial IVH or as a failure to wean off EVD. Such patients may require permanent ventriculoperitoneal shunt [<a href="#rid40">40</a>]. Approximately 30 to 50 percent of patients with IVH require a shunt placement [<a href="#rid16">16,57,64,71,78-81</a>]. (See  <a class="medical medical_review" href="/d/html/5069.html" rel="external">"Normal pressure hydrocephalus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Late recurrence of intracerebral hemorrhage or IVH – Recurrent hemorrhage is uncommonly reported after IVH. In one series, 2 of 14 survivors had a subsequent intracerebral hemorrhage [<a href="#rid12">12</a>], while in another series there was no recurrent bleeding in a group of 13 patients after 67 months [<a href="#rid11">11</a>]. The risk of this complication is likely highest in those with an unrecognized and/or unsecured vascular lesion (eg, Moyamoya) [<a href="#rid27">27,82</a>].</p><p></p><p class="headingAnchor" id="H1715615806"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/105370.html" rel="external">"Society guideline links: Stroke in adults"</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Terminology and etiologies</strong> – Intraventricular hemorrhage (IVH) can complicate intracerebral hemorrhage or subarachnoid hemorrhage (secondary IVH). Less commonly, IVH occurs in isolation (primary IVH). The most commonly identified cause of primary IVH is a vascular malformation. Up to half of patients with primary IVH do not have a cause (other than hypertension) identified. (See <a class="local">'Epidemiology and definitions'</a> above and <a class="local">'Etiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Patients with IVH usually present with sudden headache, nausea and vomiting, and impaired alertness. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation</strong> – Patients with a clinical presentation of IVH should undergo immediate noncontrast head computed tomography (CT). The primary purpose is to exclude subarachnoid hemorrhage and to identify the IVH and evaluate its severity and potential for obstructive hydrocephalus. (See <a class="local">'Computed tomography'</a> above.)</p><p></p><p class="bulletIndent1">Individuals with primary IVH should have magnetic resonance imaging with magnetic resonance angiography and/or conventional angiography to identify the underlying etiology, particularly a vascular malformation or aneurysm that may require surgical intervention. (See <a class="local">'Other neuroimaging studies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Monitoring</strong> – Because acute obstructive hydrocephalus often complicates IVH that involves the third and fourth ventricles, such patients should be closely monitored. When neurologic deterioration occurs, emergent CT scan should be done to exclude the development of obstructive hydrocephalus or recurrent hemorrhage. (See <a class="local">'General measures'</a> above and <a class="local">'Computed tomography'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Blood pressure</strong> – The optimal blood pressure management in patients with IVH is uncertain. For patients with IVH and elevated blood pressure, intravenous antihypertensives such as <a class="drug drug_general" data-topicid="9540" href="/d/drug information/9540.html" rel="external">labetalol</a> or <a class="drug drug_general" data-topicid="9697" href="/d/drug information/9697.html" rel="external">nicardipine</a> may be used to lower blood pressure gradually while maintaining adequate cerebral perfusion. Aggressive blood pressure lowering may minimize the risk of further hemorrhage but must be weighed against the risk of decreased cerebral perfusion in patients with increased ICP. (See <a class="local">'Blood pressure management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>External ventricular drain</strong> – We recommend external ventricular drainage (EVD) for patients with neurologic deterioration that occurs with ventricular enlargement over conservative management (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). An EVD can reduce clot burden, treat hydrocephalus, and facilitate ICP monitoring. (See <a class="local">'External ventricular drain'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Additional management options</strong> – The use of intraventricular thrombolysis involves shared decision-making and after assessing individual risks and benefits and is reserved for patients at experienced centers with established protocols. (See <a class="local">'Intraventricular thrombolysis'</a> above and <a class="local">'Lumbar drainage'</a> above.)</p><p></p><p class="headingAnchor" id="H97248249"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges James Pacelli Jr, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Darby DG, Donnan GA, Saling MA, et al. Primary intraventricular hemorrhage: clinical and neuropsychological findings in a prospective stroke series. Neurology 1988; 38:68.</a></li><li><a class="nounderline abstract_t">Flint AC, Roebken A, Singh V. Primary intraventricular hemorrhage: yield of diagnostic angiography and clinical outcome. Neurocrit Care 2008; 8:330.</a></li><li><a class="nounderline abstract_t">Hanley DF. Intraventricular hemorrhage: severity factor and treatment target in spontaneous intracerebral hemorrhage. Stroke 2009; 40:1533.</a></li><li><a class="nounderline abstract_t">Nyquist P, Hanley DF. The use of intraventricular thrombolytics in intraventricular hemorrhage. J Neurol Sci 2007; 261:84.</a></li><li><a class="nounderline abstract_t">Maas MB, Nemeth AJ, Rosenberg NF, et al. Delayed intraventricular hemorrhage is common and worsens outcomes in intracerebral hemorrhage. Neurology 2013; 80:1295.</a></li><li><a class="nounderline abstract_t">Biffi A, Battey TW, Ayres AM, et al. Warfarin-related intraventricular hemorrhage: imaging and outcome. Neurology 2011; 77:1840.</a></li><li><a class="nounderline abstract_t">LeRoux PD, Haglund MM, Newell DW, et al. Intraventricular hemorrhage in blunt head trauma: an analysis of 43 cases. Neurosurgery 1992; 31:678.</a></li><li><a class="nounderline abstract_t">Inamasu J, Hori S, Aikawa N. Traumatic intraventricular hemorrhage causing talk and deteriorate syndrome. Am J Emerg Med 2001; 19:167.</a></li><li><a class="nounderline abstract_t">Atzema C, Mower WR, Hoffman JR, et al. Prevalence and prognosis of traumatic intraventricular hemorrhage in patients with blunt head trauma. J Trauma 2006; 60:1010.</a></li><li><a class="nounderline abstract_t">Angelopoulos M, Gupta SR, Azat Kia B. Primary intraventricular hemorrhage in adults: clinical features, risk factors, and outcome. Surg Neurol 1995; 44:433.</a></li><li><a class="nounderline abstract_t">Martí-Fàbregas J, Piles S, Guardia E, Martí-Vilalta JL. Spontaneous primary intraventricular hemorrhage: clinical data, etiology and outcome. J Neurol 1999; 246:287.</a></li><li><a class="nounderline abstract_t">Passero S, Ulivelli M, Reale F. Primary intraventricular haemorrhage in adults. Acta Neurol Scand 2002; 105:115.</a></li><li><a class="nounderline abstract_t">Findlay JM. Intraventricular hemorrhage. Neurosurgery Quarterly 2000; 10:182.</a></li><li><a class="nounderline abstract_t">Zhu XL, Chan MS, Poon WS. Spontaneous intracranial hemorrhage: which patients need diagnostic cerebral angiography? A prospective study of 206 cases and review of the literature. Stroke 1997; 28:1406.</a></li><li><a class="nounderline abstract_t">Roos YB, Hasan D, Vermeulen M. Outcome in patients with large intraventricular haemorrhages: a volumetric study. J Neurol Neurosurg Psychiatry 1995; 58:622.</a></li><li><a class="nounderline abstract_t">Goh KY, Poon WS. Recombinant tissue plasminogen activator for the treatment of spontaneous adult intraventricular hemorrhage. Surg Neurol 1998; 50:526.</a></li><li><a class="nounderline abstract_t">Kumar K, Demeria DD, Verma A. Recombinant tissue plasminogen activator in the treatment of intraventricular hemorrhage secondary to periventricular arteriovenous malformation before surgery: case report. Neurosurgery 2003; 52:964.</a></li><li><a class="nounderline abstract_t">Irie F, Fujimoto S, Uda K, et al. Primary intraventricular hemorrhage from dural arteriovenous fistula. J Neurol Sci 2003; 215:115.</a></li><li><a class="nounderline abstract_t">Gerard E, Frontera JA, Wright CB. Vasospasm and cerebral infarction following isolated intraventricular hemorrhage. Neurocrit Care 2007; 7:257.</a></li><li><a class="nounderline abstract_t">Okamura A, Goto S, Sato K, Ushio Y. Central neurocytoma with hemorrhagic onset. Surg Neurol 1995; 43:252.</a></li><li><a class="nounderline abstract_t">Lee EJ, Choi KH, Kang SW, Lee IW. Intraventricular hemorrhage caused by lateral ventricular meningioma: a case report. Korean J Radiol 2001; 2:105.</a></li><li><a class="nounderline abstract_t">Vates GE, Arthur KA, Ojemann SG, et al. A neurocytoma and an associated lenticulostriate artery aneurysm presenting with intraventricular hemorrhage: case report. Neurosurgery 2001; 49:721.</a></li><li><a class="nounderline abstract_t">Lindboe CF, Stolt-Nielsen A, Dale LG. Hemorrhage in a highly vascularized subependymoma of the septum pellucidum: case report. Neurosurgery 1992; 31:741.</a></li><li><a class="nounderline abstract_t">Smets K, Salgado R, Simons PJ, et al. Central neurocytoma presenting with intraventricular hemorrhage: case report and review of literature. Acta Neurol Belg 2005; 105:218.</a></li><li><a class="nounderline abstract_t">Zuccaro G, Sosa F, Cuccia V, et al. Lateral ventricle tumors in children: a series of 54 cases. Childs Nerv Syst 1999; 15:774.</a></li><li><a class="nounderline abstract_t">Akamatsu Y, Utsunomiya A, Suzuki S, et al. Subependymoma in the lateral ventricle manifesting as intraventricular hemorrhage. Neurol Med Chir (Tokyo) 2010; 50:1020.</a></li><li><a class="nounderline abstract_t">Hamada J, Hashimoto N, Tsukahara T. Moyamoya disease with repeated intraventricular hemorrhage due to aneurysm rupture. Report of two cases. J Neurosurg 1994; 80:328.</a></li><li><a class="nounderline abstract_t">Khan M, Novakovic RL, Rosengart AJ. Intraventricular hemorrhage disclosing neurofibromatosis 1 and moyamoya phenomena. Arch Neurol 2006; 63:1653.</a></li><li><a class="nounderline abstract_t">Jabbour R, Taher A, Shamseddine A, Atweh SF. Moyamoya syndrome with intraventricular hemorrhage in an adult with factor V Leiden mutation. Arch Neurol 2005; 62:1144.</a></li><li><a class="nounderline abstract_t">Nah HW, Kwon SU, Kang DW, et al. Moyamoya disease-related versus primary intracerebral hemorrhage: [corrected] location and outcomes are different. Stroke 2012; 43:1947.</a></li><li><a class="nounderline abstract_t">Yu Z, Guo R, Zheng J, et al. Comparison of Acute Moyamoya Disease-Related and Idiopathic Primary Intraventricular Hemorrhage in Adult Patients. World Neurosurg 2019; 125:e313.</a></li><li><a class="nounderline abstract_t">Ionita CC, Ferrara J, McDonagh DL, et al. Systemic hemostasis with recombinant-activated factor VII followed by local thrombolysis with recombinant tissue plasminogen activator in intraventricular hemorrhage. Neurocrit Care 2005; 3:246.</a></li><li><a class="nounderline abstract_t">Kiymaz N, Demir O, Cirak B. Is external ventricular drainage useful in primary intraventricular hemorrhages? Adv Ther 2005; 22:447.</a></li><li><a class="nounderline abstract_t">Lin X, Cao Y, Yan J, et al. Risk Factors for Early Intracerebral Hemorrhage after Intravenous Thrombolysis with Alteplase. J Atheroscler Thromb 2020; 27:1176.</a></li><li><a class="nounderline abstract_t">Challa VR, Richards F 2nd, Davis CH Jr. Intraventricular hemorrhage from pituitary apoplexy. Surg Neurol 1981; 16:360.</a></li><li><a class="nounderline abstract_t">Kishimoto M, Arakawa KC. A patient with wegener granulomatosis and intraventricular hemorrhage. J Clin Rheumatol 2003; 9:354.</a></li><li><a class="nounderline abstract_t">Imanse J, Vanneste J. Intraventricular hemorrhage following amphetamine abuse. Neurology 1990; 40:1318.</a></li><li><a class="nounderline abstract_t">Ziai WC, Triantaphyllopoulou A, Razumovsky AY, Hanley DF. Treatment of sympathomimetic induced intraventricular hemorrhage with intraventricular urokinase. J Stroke Cerebrovasc Dis 2003; 12:276.</a></li><li><a class="nounderline abstract_t">Rohde V, Schaller C, Hassler WE. Intraventricular recombinant tissue plasminogen activator for lysis of intraventricular haemorrhage. J Neurol Neurosurg Psychiatry 1995; 58:447.</a></li><li><a class="nounderline abstract_t">Nyquist P, LeDroux S, Geocadin R. Thrombolytics in intraventricular hemorrhage. Curr Neurol Neurosci Rep 2007; 7:522.</a></li><li><a class="nounderline abstract_t">Nishikawa T, Ueba T, Kajiwara M, et al. A priority treatment of the intraventricular hemorrhage (IVH) should be performed in the patients suffering intracerebral hemorrhage with large IVH. Clin Neurol Neurosurg 2009; 111:450.</a></li><li><a class="nounderline abstract_t">Roh DJ, Asonye IS, Carvalho Poyraz F, et al. Intraventricular Hemorrhage Expansion in the CLEAR III Trial: A Post Hoc Exploratory Analysis. Stroke 2022; 53:1847.</a></li><li><a class="nounderline abstract_t">Nawabi J, Schlunk F, Dell'Orco A, et al. Non-contrast computed tomography features predict intraventricular hemorrhage growth. Eur Radiol 2023; 33:7807.</a></li><li><a class="nounderline abstract_t">Dull C, Torbey MT. Cerebral vasospasm associated with intraventricular hemorrhage. Neurocrit Care 2005; 3:150.</a></li><li><a class="nounderline abstract_t">Maeda K, Kurita H, Nakamura T, et al. Occurrence of severe vasospasm following intraventricular hemorrhage from an arteriovenous malformation. Report of two cases. J Neurosurg 1997; 87:436.</a></li><li><a class="nounderline abstract_t">Fluss R, Laarakker A, Nakhla J, et al. Prolonged delayed vasospasm in the setting of nonaneurysmal intraventricular hemorrhage. Surg Neurol Int 2019; 10:29.</a></li><li><a class="nounderline abstract_t">Graeb DA, Robertson WD, Lapointe JS, et al. Computed tomographic diagnosis of intraventricular hemorrhage. Etiology and prognosis. Radiology 1982; 143:91.</a></li><li><a class="nounderline abstract_t">Morgan TC, Dawson J, Spengler D, et al. The Modified Graeb Score: an enhanced tool for intraventricular hemorrhage measurement and prediction of functional outcome. Stroke 2013; 44:635.</a></li><li><a class="nounderline abstract_t">Hallevi H, Dar NS, Barreto AD, et al. The IVH score: a novel tool for estimating intraventricular hemorrhage volume: clinical and research implications. Crit Care Med 2009; 37:969.</a></li><li><a class="nounderline abstract_t">Kiphuth IC, Huttner HB, Struffert T, et al. Sonographic monitoring of ventricle enlargement in posthemorrhagic hydrocephalus. Neurology 2011; 76:858.</a></li><li><a class="nounderline abstract_t">Greenberg SM, Ziai WC, Cordonnier C, et al. 2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association. Stroke 2022; 53:e282.</a></li><li><a class="nounderline abstract_t">Narotam PK, Puri V, Roberts JM, et al. Management of hypertensive emergencies in acute brain disease: evaluation of the treatment effects of intravenous nicardipine on cerebral oxygenation. J Neurosurg 2008; 109:1065.</a></li><li class="breakAll">Findlay JM. Intraventricular Hemorrhage. In: Pathophysiology Diagnosis and Managment, 4th ed, Mohr JPC D, Grotta J, Weir B, Wolf P (Eds).</li><li><a class="nounderline abstract_t">Pfausler B, Beer R, Engelhardt K, et al. Cell index--a new parameter for the early diagnosis of ventriculostomy (external ventricular drainage)-related ventriculitis in patients with intraventricular hemorrhage? Acta Neurochir (Wien) 2004; 146:477.</a></li><li><a class="nounderline abstract_t">Nieuwkamp DJ, de Gans K, Rinkel GJ, Algra A. Treatment and outcome of severe intraventricular extension in patients with subarachnoid or intracerebral hemorrhage: a systematic review of the literature. J Neurol 2000; 247:117.</a></li><li><a class="nounderline abstract_t">Vereecken KK, Van Havenbergh T, De Beuckelaar W, et al. Treatment of intraventricular hemorrhage with intraventricular administration of recombinant tissue plasminogen activator A clinical study of 18 cases. Clin Neurol Neurosurg 2006; 108:451.</a></li><li><a class="nounderline abstract_t">Fountas KN, Kapsalaki EZ, Parish DC, et al. Intraventricular administration of rt-PA in patients with intraventricular hemorrhage. South Med J 2005; 98:767.</a></li><li><a class="nounderline abstract_t">Staykov D, Huttner HB, Struffert T, et al. Intraventricular fibrinolysis and lumbar drainage for ventricular hemorrhage. Stroke 2009; 40:3275.</a></li><li><a class="nounderline abstract_t">Gaberel T, Magheru C, Parienti JJ, et al. Intraventricular fibrinolysis versus external ventricular drainage alone in intraventricular hemorrhage: a meta-analysis. Stroke 2011; 42:2776.</a></li><li><a class="nounderline abstract_t">Huttner HB, Tognoni E, Bardutzky J, et al. Influence of intraventricular fibrinolytic therapy with rt-PA on the long-term outcome of treated patients with spontaneous basal ganglia hemorrhage: a case-control study. Eur J Neurol 2008; 15:342.</a></li><li><a class="nounderline abstract_t">Naff NJ, Hanley DF, Keyl PM, et al. Intraventricular thrombolysis speeds blood clot resolution: results of a pilot, prospective, randomized, double-blind, controlled trial. Neurosurgery 2004; 54:577.</a></li><li><a class="nounderline abstract_t">Findlay JM, Grace MG, Weir BK. Treatment of intraventricular hemorrhage with tissue plasminogen activator. Neurosurgery 1993; 32:941.</a></li><li><a class="nounderline abstract_t">Naff NJ, Carhuapoma JR, Williams MA, et al. Treatment of intraventricular hemorrhage with urokinase : effects on 30-Day survival. Stroke 2000; 31:841.</a></li><li><a class="nounderline abstract_t">Coplin WM, Vinas FC, Agris JM, et al. A cohort study of the safety and feasibility of intraventricular urokinase for nonaneurysmal spontaneous intraventricular hemorrhage. Stroke 1998; 29:1573.</a></li><li><a class="nounderline abstract_t">Rainov NG, Burkert WL. Urokinase infusion for severe intraventricular haemorrhage. Acta Neurochir (Wien) 1995; 134:55.</a></li><li><a class="nounderline abstract_t">van Solinge TS, Muskens IS, Kavouridis VK, et al. Fibrinolytics and Intraventricular Hemorrhage: A Systematic Review and Meta-analysis. Neurocrit Care 2020; 32:262.</a></li><li><a class="nounderline abstract_t">Hanley DF, Lane K, McBee N, et al. Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial. Lancet 2017; 389:603.</a></li><li><a class="nounderline abstract_t">Naff N, Williams MA, Keyl PM, et al. Low-dose recombinant tissue-type plasminogen activator enhances clot resolution in brain hemorrhage: the intraventricular hemorrhage thrombolysis trial. Stroke 2011; 42:3009.</a></li><li><a class="nounderline abstract_t">Schwarz S, Schwab S, Steiner HH, Hacke W. Secondary hemorrhage after intraventricular fibrinolysis: a cautionary note: a report of two cases. Neurosurgery 1998; 42:659.</a></li><li><a class="nounderline abstract_t">Pollock GA, Shaibani A, Awad I, et al. Intraventricular hemorrhage secondary to intranidal aneurysm rupture-successful management by arteriovenous malformation embolization followed by intraventricular tissue plasminogen activator: case report. Neurosurgery 2011; 68:E581.</a></li><li><a class="nounderline abstract_t">Varelas PN, Rickert KL, Cusick J, et al. Intraventricular hemorrhage after aneurysmal subarachnoid hemorrhage: pilot study of treatment with intraventricular tissue plasminogen activator. Neurosurgery 2005; 56:205.</a></li><li><a class="nounderline abstract_t">Findlay JM, Jacka MJ. Cohort study of intraventricular thrombolysis with recombinant tissue plasminogen activator for aneurysmal intraventricular hemorrhage. Neurosurgery 2004; 55:532.</a></li><li><a class="nounderline abstract_t">Mayfrank L, Rohde V, Gilsbach JM. Fibrinolytic treatment of intraventricular haemorrhage preceding surgical repair of ruptured aneurysms and arteriovenous malformations. Br J Neurosurg 1999; 13:128.</a></li><li><a class="nounderline abstract_t">Herrick DB, Ziai WC, Thompson CB, et al. Systemic hematologic status following intraventricular recombinant tissue-type plasminogen activator for intraventricular hemorrhage: the CLEAR IVH Study Group. Stroke 2011; 42:3631.</a></li><li><a class="nounderline abstract_t">Engelhard HH, Andrews CO, Slavin KV, Charbel FT. Current management of intraventricular hemorrhage. Surg Neurol 2003; 60:15.</a></li><li><a class="nounderline abstract_t">Staykov D, Kuramatsu JB, Bardutzky J, et al. Efficacy and safety of combined intraventricular fibrinolysis with lumbar drainage for prevention of permanent shunt dependency after intracerebral hemorrhage with severe ventricular involvement: A randomized trial and individual patient data meta-analysis. Ann Neurol 2017; 81:93.</a></li><li><a class="nounderline abstract_t">Staykov D, Volbers B, Wagner I, et al. Prognostic significance of third ventricle blood volume in intracerebral haemorrhage with severe ventricular involvement. J Neurol Neurosurg Psychiatry 2011; 82:1260.</a></li><li class="breakAll">Findlay JM. Intraventricular Hemorrhage. In: Stroke: Pathophysiology Diagnosis and Management, 4th ed, Mohr JP, Choi DW, Grotta JC, Weir B, Wolf PA (Eds), Churchill Livingstone 2004. p.1231.</li><li><a class="nounderline abstract_t">Vale FL, Bradley EL, Fisher WS 3rd. The relationship of subarachnoid hemorrhage and the need for postoperative shunting. J Neurosurg 1997; 86:462.</a></li><li><a class="nounderline abstract_t">Graff-Radford NR, Torner J, Adams HP Jr, Kassell NF. Factors associated with hydrocephalus after subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. Arch Neurol 1989; 46:744.</a></li><li><a class="nounderline abstract_t">Miller C, Tsivgoulis G, Nakaji P. Predictors of ventriculoperitoneal shunting after spontaneous intraparenchymal hemorrhage. Neurocrit Care 2008; 8:235.</a></li><li><a class="nounderline abstract_t">Kobayashi E, Saeki N, Oishi H, et al. Long-term natural history of hemorrhagic moyamoya disease in 42 patients. J Neurosurg 2000; 93:976.</a></li></ol></div><div id="topicVersionRevision">Topic 1116 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3257294" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Primary intraventricular hemorrhage: clinical and neuropsychological findings in a prospective stroke series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18320145" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Primary intraventricular hemorrhage: yield of diagnostic angiography and clinical outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19246695" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Intraventricular hemorrhage: severity factor and treatment target in spontaneous intracerebral hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17553525" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The use of intraventricular thrombolytics in intraventricular hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23516315" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Delayed intraventricular hemorrhage is common and worsens outcomes in intracerebral hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22049204" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Warfarin-related intraventricular hemorrhage: imaging and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1407453" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Intraventricular hemorrhage in blunt head trauma: an analysis of 43 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11239267" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Traumatic intraventricular hemorrhage causing talk and deteriorate syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16688063" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Prevalence and prognosis of traumatic intraventricular hemorrhage in patients with blunt head trauma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8629227" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Primary intraventricular hemorrhage in adults: clinical features, risk factors, and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10367697" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Spontaneous primary intraventricular hemorrhage: clinical data, etiology and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11903121" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Primary intraventricular haemorrhage in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Intraventricular hemorrhage</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9227692" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Spontaneous intracranial hemorrhage: which patients need diagnostic cerebral angiography? A prospective study of 206 cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7745414" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Outcome in patients with large intraventricular haemorrhages: a volumetric study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9870812" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Recombinant tissue plasminogen activator for the treatment of spontaneous adult intraventricular hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12657195" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Recombinant tissue plasminogen activator in the treatment of intraventricular hemorrhage secondary to periventricular arteriovenous malformation before surgery: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14568138" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Primary intraventricular hemorrhage from dural arteriovenous fistula.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17522787" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Vasospasm and cerebral infarction following isolated intraventricular hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7792688" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Central neurocytoma with hemorrhagic onset.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11752978" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Intraventricular hemorrhage caused by lateral ventricular meningioma: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11523685" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A neurocytoma and an associated lenticulostriate artery aneurysm presenting with intraventricular hemorrhage: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1407461" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Hemorrhage in a highly vascularized subependymoma of the septum pellucidum: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16482873" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Central neurocytoma presenting with intraventricular hemorrhage: case report and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10603022" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Lateral ventricle tumors in children: a series of 54 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21123990" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Subependymoma in the lateral ventricle manifesting as intraventricular hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8283274" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Moyamoya disease with repeated intraventricular hemorrhage due to aneurysm rupture. Report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17101839" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Intraventricular hemorrhage disclosing neurofibromatosis 1 and moyamoya phenomena.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16009774" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Moyamoya syndrome with intraventricular hemorrhage in an adult with factor V Leiden mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22693130" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Moyamoya disease-related versus primary intracerebral hemorrhage: [corrected] location and outcomes are different.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30685378" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Comparison of Acute Moyamoya Disease-Related and Idiopathic Primary Intraventricular Hemorrhage in Adult Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16377837" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Systemic hemostasis with recombinant-activated factor VII followed by local thrombolysis with recombinant tissue plasminogen activator in intraventricular hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16418153" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Is external ventricular drainage useful in primary intraventricular hemorrhages?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32115471" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Risk Factors for Early Intracerebral Hemorrhage after Intravenous Thrombolysis with Alteplase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7336321" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Intraventricular hemorrhage from pituitary apoplexy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17043443" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A patient with wegener granulomatosis and intraventricular hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2381547" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Intraventricular hemorrhage following amphetamine abuse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17903940" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Treatment of sympathomimetic induced intraventricular hemorrhage with intraventricular urokinase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7738552" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Intraventricular recombinant tissue plasminogen activator for lysis of intraventricular haemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17999899" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Thrombolytics in intraventricular hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19231066" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A priority treatment of the intraventricular hemorrhage (IVH) should be performed in the patients suffering intracerebral hemorrhage with large IVH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35086362" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Intraventricular Hemorrhage Expansion in the CLEAR III Trial: A Post Hoc Exploratory Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37212845" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Non-contrast computed tomography features predict intraventricular hemorrhage growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16174885" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Cerebral vasospasm associated with intraventricular hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9285611" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Occurrence of severe vasospasm following intraventricular hemorrhage from an arteriovenous malformation. Report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31528367" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Prolonged delayed vasospasm in the setting of nonaneurysmal intraventricular hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6977795" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Computed tomographic diagnosis of intraventricular hemorrhage. Etiology and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23370203" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The Modified Graeb Score: an enhanced tool for intraventricular hemorrhage measurement and prediction of functional outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19237905" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The IVH score: a novel tool for estimating intraventricular hemorrhage volume: clinical and research implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21288979" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Sonographic monitoring of ventricle enlargement in posthemorrhagic hydrocephalus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35579034" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : 2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19035721" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Management of hypertensive emergencies in acute brain disease: evaluation of the treatment effects of intravenous nicardipine on cerebral oxygenation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19035721" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Management of hypertensive emergencies in acute brain disease: evaluation of the treatment effects of intravenous nicardipine on cerebral oxygenation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15118885" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Cell index--a new parameter for the early diagnosis of ventriculostomy (external ventricular drainage)-related ventriculitis in patients with intraventricular hemorrhage?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10751114" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Treatment and outcome of severe intraventricular extension in patients with subarachnoid or intracerebral hemorrhage: a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16139422" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Treatment of intraventricular hemorrhage with intraventricular administration of recombinant tissue plasminogen activator A clinical study of 18 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16144170" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Intraventricular administration of rt-PA in patients with intraventricular hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19679848" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Intraventricular fibrinolysis and lumbar drainage for ventricular hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21817146" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Intraventricular fibrinolysis versus external ventricular drainage alone in intraventricular hemorrhage: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18312407" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Influence of intraventricular fibrinolytic therapy with rt-PA on the long-term outcome of treated patients with spontaneous basal ganglia hemorrhage: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15028130" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Intraventricular thrombolysis speeds blood clot resolution: results of a pilot, prospective, randomized, double-blind, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8327096" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Treatment of intraventricular hemorrhage with tissue plasminogen activator.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10753985" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Treatment of intraventricular hemorrhage with urokinase : effects on 30-Day survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9707195" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : A cohort study of the safety and feasibility of intraventricular urokinase for nonaneurysmal spontaneous intraventricular hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7668129" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Urokinase infusion for severe intraventricular haemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31376141" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Fibrinolytics and Intraventricular Hemorrhage: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28081952" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21868730" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Low-dose recombinant tissue-type plasminogen activator enhances clot resolution in brain hemorrhage: the intraventricular hemorrhage thrombolysis trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9527003" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Secondary hemorrhage after intraventricular fibrinolysis: a cautionary note: a report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21654560" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Intraventricular hemorrhage secondary to intranidal aneurysm rupture-successful management by arteriovenous malformation embolization followed by intraventricular tissue plasminogen activator: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15670368" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Intraventricular hemorrhage after aneurysmal subarachnoid hemorrhage: pilot study of treatment with intraventricular tissue plasminogen activator.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15335420" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Cohort study of intraventricular thrombolysis with recombinant tissue plasminogen activator for aneurysmal intraventricular hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10616579" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Fibrinolytic treatment of intraventricular haemorrhage preceding surgical repair of ruptured aneurysms and arteriovenous malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21940973" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Systemic hematologic status following intraventricular recombinant tissue-type plasminogen activator for intraventricular hemorrhage: the CLEAR IVH Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12865003" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Current management of intraventricular hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27888608" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Efficacy and safety of combined intraventricular fibrinolysis with lumbar drainage for prevention of permanent shunt dependency after intracerebral hemorrhage with severe ventricular involvement: A randomized trial and individual patient data meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21515556" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Prognostic significance of third ventricle blood volume in intracerebral haemorrhage with severe ventricular involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21515556" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Prognostic significance of third ventricle blood volume in intracerebral haemorrhage with severe ventricular involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9046303" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : The relationship of subarachnoid hemorrhage and the need for postoperative shunting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2742543" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Factors associated with hydrocephalus after subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17928961" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Predictors of ventriculoperitoneal shunting after spontaneous intraparenchymal hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11117870" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Long-term natural history of hemorrhagic moyamoya disease in 42 patients.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
